MedTrace Logo

Safety and Efficacy of YH14617 in Diabetes Mellitus

NCT01507038 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2015-02-18

No results posted yet for this study

Summary

The objective of this study is to assess the safety, efficacy and pharmacokinetic of YH14617 after once weekly or biweekly injection in patients with type 2 Diabetes Mellitus to investigate the optimal recommended dosage. Study period is 20 weeks including 12 weeks of treatment period and 8weeks of follow-up period without treatment.

Conditions

Interventions

DRUG

YH14617

1mg once weekly

DRUG

YH14617

1.6mg once weekly

DRUG

YH14617

2mg once biweekly

DRUG

Placebo

Once weekly

Sponsors & Collaborators

  • Peptron, Inc.

    collaborator INDUSTRY

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Dong-Seop Choi, MD, PhD. · Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2015-01-31
Completion
2015-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01507038 on ClinicalTrials.gov